Recent research led by Charles Cox, M.D., at the University of Texas Health Science Center at Houston Medical School, found that multipotent adult progenitor cell (MAPC) therapy could promote lasting cognitive improvement in addition to reduction of inflammation after traumatic brain injury. The study was published in Stem Cells Translational Medicine.
Cellular damage in the brain after traumatic injury could cause severe neurological impairment and inflammation, but there is few treatment options exist. Currently, about 50% of patients with severe head injuries need surgery to remove or repair broken blood vessels or brain tissue.
Read other articles related to brain injury research:
[feed url=”http://bionews-tx.com/news/news-tags/brain-damage/feed” number=”5″ ]
Cox’s team injected MAPC in two groups of brain-injured mice at 2 hours and 24 hours after the mice were injured. The dose was 2 million cells/ kg and 10 million cells/ kg, respectively. The results revealed that the mice received 10 million cells/ kg of MAPC and showed less inflammation and significant, continuous gains in cognitive function.
“Based on our data, we saw improved spatial learning, improved motor deficits and fewer active antibodies in the mice that were given the stronger concentration of MAPCs,” said Cox.
The study indicates that intravenous injection of MAPCs may become a viable treatment for people with traumatic brain injury in the future, he said.